Search

Your search keyword '"Antimetabolites administration & dosage"' showing total 572 results

Search Constraints

Start Over You searched for: Descriptor "Antimetabolites administration & dosage" Remove constraint Descriptor: "Antimetabolites administration & dosage"
572 results on '"Antimetabolites administration & dosage"'

Search Results

301. Long-term administration of clodronate does not prevent fracture healing in rats.

302. Clodronate treatment of established bone loss in cardiac recipients: a randomized study.

303. Pancreatic concentrations of cefepime in experimental necrotizing pancreatitis.

304. Comparison of in vivo lymphocyte proliferation between allogeneic and xenogeneic heart transplantation in mice.

305. [Injuries of pancreatoduodenal organs].

306. Buccal delivery of acyclovir from films based on chitosan and polyacrylic acid.

307. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].

308. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen.

309. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

310. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy.

311. Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections.

312. Poly(L-glutamic acid)--anticancer drug conjugates.

313. Bisphosphonates and tumor burden.

314. 5-Fluorouracil-induced intestinal toxicity: what determines the severity of damage to murine intestinal crypt epithelia?

315. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.

316. Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration.

317. Multi-antioxidant supplementation does not prevent an increase in gut permeability after lower torso ischemia and reperfusion in humans.

318. Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: preclinical consideration.

319. Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD).

320. A new delivery system for 5-fluorouracil using prodrug and converting enzyme.

321. Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis.

322. [Antimetabolites in glaucoma surgery--long-term results].

323. CD8 alpha-deficient mice are highly susceptible to 5-fluorouracil-induced lethality.

324. Immunolesion of hindbrain catecholaminergic projections to the medial hypothalamus attenuates penile reflexive erections and alters hypothalamic peptide mRNA.

325. Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone.

326. [New techniques for optimization of thiopurine therapy in leukemia and transplantation].

327. Late-onset transconjunctival oozing and point leak of aqueous humor from filtering bleb after trabeculectomy.

328. Endocrinological assessment of toxic effects on the male reproductive system in rats treated with 5-fluorouracil for 2 or 4 weeks.

329. Needling revision with subconjunctival 5-fluorouracil in failing filtering blebs.

330. Liposomes--an invaluable tool in bisphosphonate research.

331. Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study.

332. Evaluation of d,l-ethionine as a mechanism for pancreatic islet regeneration in dogs.

333. Modern therapy for Paget's disease of bone: focus on bisphosphonates.

334. Formation and characterisation of non-toxic anionic liposomes for delivery of therapeutic agents to the pulmonary airways.

335. [Prophylactics of acute pancreatitis in pancreatic-duodenal resection].

336. Successful treatment of ocular leishmaniasis.

337. Five-year follow-up of LSL trabeculectomies with low dosage mitomycin-C in primary open-angle glaucoma.

338. Single intraoperative application of 5-Fluorouracil versus placebo in low-risk trabeculectomy surgery: a randomized trial.

339. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.

340. Slow release of the antimetabolite 5-fluorouracil (5-FU) from modified Baerveldt glaucoma drains to prolong drain function.

341. Comparison of external dacryocystorhinostomy and 5-fluorouracil augmented endonasal laser dacryocystorhinostomy. A retrospective review.

342. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.

343. The National Survey of Trabeculectomy. II. Variations in operative technique and outcome.

344. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro.

345. Effects of 5-fluorouracil on mitogen-induced costimulatory capacity of accessory cells from rat oral mucosa and dental pulp.

346. Formulation factors for preparing ocular biodegradable delivery system of 5-fluorouracil microparticles.

347. Modulation of wound healing after glaucoma surgery.

349. Pharmacoeconomic considerations in the management of acute tumor lysis syndrome.

350. Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications.

Catalog

Books, media, physical & digital resources